Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Overview
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Bavarian Nordic AS
IDBiologics Inc
Sigmovir Biosystems Inc
Visterra Inc
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles
MVA-BN RSV - Drug Profile
Product Description
Mechanism Of Action
History of Events
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
RSV - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRL-3D3 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VIS-RSV - Drug Profile
Product Description
Mechanism Of Action
History of Events
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Products
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Product Development Milestones
Featured News & Press Releases
Nov 14, 2022: Chinese CDE grants IND clearance for Nuance’s RSV vaccine trial
Jun 28, 2022: Bavarian Nordic announces grant of PRIME eligibility from the European Medicines Agency for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults
Apr 20, 2022: Bavarian Nordic announces initiation of a global phase 3 clinical trial of its RSV vaccine candidate in older adults
Feb 22, 2022: Open Orphan : FDA breakthrough desigtion for Big Pharma RSV candidate
Feb 14, 2022: Bavarian Nordic announces Breakthrough Therapy Desigtion for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults
Dec 06, 2021: Bavarian Nordic commits to initiating phase 3 trial of RSV vaccine candidate and to strengthening its capital base
Sep 07, 2021: Open Orphan: Positive results from RSV Human Challenge Study
Sep 01, 2021: Bavarian Nordic reports positive results from human challenge trial of its RSV vaccine candidate
Aug 08, 2018: Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
Mar 06, 2018: Bavarian Nordic Announces Additiol Positive Data from a Phase 2 Study of its Universal RSV Vaccine
Nov 09, 2017: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
Sep 21, 2017: Bavarian Nordic Provides Update on its Universal RSV Vaccine
Jun 27, 2017: Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
Feb 23, 2017: Updated Phase 1 Data Show Bavarian Nordic’s Vaccine Candidate Induces a Broad and Durable Immune Response against RSV
Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Bavarian Nordic AS, 2022
Pipeline by IDBiologics Inc, 2022
Pipeline by Sigmovir Biosystems Inc, 2022
Pipeline by Visterra Inc, 2022
Dormant Projects, 2022